Appili gets FDA approval to expand the clinical trial of favipiravir

Appili gets FDA approval to expand the clinical trial of favipiravir

Published: 20 hours ago By Pankaj Singh

Biopharmaceutical major, Appili Therapeutics Inc., has reportedly announced that it has received the approval of the U.S. Food and Drug Administration (FDA) over its recently filed investigational new drug application for favipiravir, a bro....

Saudi begins Phase III clinical trials of Chinese COVID-19 vaccine

The Ministry of Health, Saudi Arabia, has reportedly announced that it will begin the third phase of clinical trials for a COVID-19 vaccine, as part of its cooperation with China’s CanSino Biologics Inc. The trials will be conducted i....

Montero inks agreement to acquire Isabella Gold Silver Project

Montero Mining and Exploration Ltd. has reportedly inked a Binding Purchase & Sale Agreement to acquire a 100% or full interest in a private company in Chile. ChileCo holds several mineral rights to exploration claims on the Isabella Go....

Amazon cleared by UK regulators to buy 16% stake in Deliveroo

The eCommerce giant Amazon has been granted permission to purchase a minority stake in the U.K-based food delivery start-up Deliveroo. The firm was able to convince regulators that the deal would not be detrimental to competition. In May o....

PharmaCyte to submit IND application to FDA for clinical trial in LAPC

PharmaCyte Biotech, a clinical-stage biotechnology company, is reportedly set to submit an IND (Investigational New Drug) application to the U.S. FDA. The IND application is related to the Phase 2b clinical trial among patients with LAPC (l....

Australia retail industry in disarray with major slump in sales

Australia’s retailers are reportedly facing a huge crisis of sorts, with the latest data depicting a massive fall in sales volumes. As the nation’s second-largest state enforces a lockdown to fight the ongoing coronavirus, Austr....

Immunic announces topline data from Phase 2 EMPhASIS, IMU-838 trial

Immunic, Inc. has recently announced positive topline results from the Phase 2 EMPhASIS trial of IMU-838, in patients with RRMS (relapsing-remitting multiple sclerosis). IMU-838 is a next-generation, orally available selective immune modula....

Industry Updates